Source: Endpoints News

Vertex Pharmaceuticals: Vertex's second-generation diabetes cell therapy fails early-stage study

Vertex Pharmaceuticals announced Friday afternoon that it won't move forward with its type 1 diabetes cell therapy that's delivered in a device meant to get rid of the need for immunosuppression ...

Read full article »
Annual Revenue
$10-50B
Employees
5.0-10K
Reshma Kewalramani's photo - President & CEO of Vertex Pharmaceuticals

President & CEO

Reshma Kewalramani

CEO Approval Rating

73/100

Read more